Rain Therapeutics Announces a Poster Presentation at the 34th EORTC/AACR/NCI Symposium

Rhea-AI Summary

Rain Therapeutics Inc. (NasdaqGS: RAIN) presented a poster on milademetan, a small molecule inhibitor targeting the MDM2-p53 complex, at the 34th EORTC/AACR/NCI Symposium in Barcelona on October 26, 2022. The presentation titled "Combination of MDM2 inhibition with milademetan and MEK inhibition leads to improved anti-tumor activity in cancer models harboring WT TP53" was led by Dr. Vijaya G. Tirunagaru. Rain Therapeutics focuses on precision oncology, utilizing a genetically-based patient selection strategy for its therapies, including milademetan, which reactivates the p53 protein.

Positive

• Successful presentation at a reputable international symposium highlights the credibility of the company's research.
• Milademetan shows promise as a therapy by potentially improving anti-tumor activity in specific cancer models.

Negative

• None.

NEWARK, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced a poster presentation at the 34th EORTC/AACR/NCI Symposium taking place on October 26-28, 2022 in Barcelona, Spain.

Abstract Title:	Combination of MDM2 inhibition with milademetan and MEK inhibition leads to improved anti-tumor activity in cancer models harboring WT TP53
Poster Session:	Molecular Targeted Agents 1
Presenter:	Vijaya G. Tirunagaru, Ph.D., Sr. Vice President and Head of Research, Rain Therapeutics, Newark, CA
Poster Session Date:	Wednesday, October 26, 2022
Location:	Exhibition Hall

A copy of the presentation materials can be accessed by visiting the "Resources” section of the Rain website after the conclusion of the presentation and will be archived on the Rain website.

About Rain Therapeutics Inc.
Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2-p53 complex that reactivates p53. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Media Contact
Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com

Investor Contact
Bob Yedid
LifeSci Advisors
+1.646.597.6989
bob@lifesciadvisors.com

FAQ

What is the focus of Rain Therapeutics Inc.?

Rain Therapeutics Inc. focuses on developing precision oncology therapeutics targeting oncogenic drivers, utilizing a genetically-based patient selection approach.

What is milademetan and its role in cancer treatment?

Milademetan is an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates the p53 protein, potentially enhancing anti-tumor response in certain cancers.

When and where did Rain Therapeutics present their research?

Rain Therapeutics presented their research on milademetan at the 34th EORTC/AACR/NCI Symposium in Barcelona on October 26, 2022.

Who presented the poster on milademetan?

The poster on milademetan was presented by Dr. Vijaya G. Tirunagaru, Sr. Vice President and Head of Research at Rain Therapeutics.

How can I access the presentation materials from Rain Therapeutics?

The presentation materials can be accessed in the "Resources" section of the Rain Therapeutics website after the conclusion of the presentation.